RT Journal Article
SR Electronic
T1 Gut microbiome compositional and functional features associate with Alzheimer’s disease pathology
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.04.24313004
DO 10.1101/2024.09.04.24313004
A1 Kang, Jea Woo
A1 Khatib, Lora A.
A1 Heston, Margo B.
A1 Dilmore, Amanda H.
A1 Labus, Jennifer S.
A1 Deming, Yuetiva
A1 Schimmel, Leyla
A1 Blach, Colette
A1 McDonald, Daniel
A1 Gonzalez, Antonio
A1 Bryant, MacKenzie
A1 Sanders, Karenina
A1 Schwartz, Lara
A1 Ulland, Tyler K.
A1 Johnson, Sterling C.
A1 Asthana, Sanjay
A1 Carlsson, Cynthia M.
A1 Chin, Nathaniel A.
A1 Blennow, Kaj
A1 Zetterberg, Henrik
A1 Rey, Federico E.
A1 ,
A1 Kaddurah-Daouk, Rima
A1 Knight, Rob
A1 Bendlin, Barbara B.
YR 2024
UL http://medrxiv.org/content/early/2024/09/05/2024.09.04.24313004.abstract
AB BACKGROUND The gut microbiome is a potentially modifiable factor in Alzheimer’s disease (AD); however, understanding of its composition and function regarding AD pathology is limited.METHODS Shallow-shotgun metagenomic data was used to analyze fecal microbiome from participants enrolled in the Wisconsin Microbiome in Alzheimer’s Risk Study, leveraging clinical data and cerebrospinal fluid (CSF) biomarkers. Differential abundance and ordinary least squares regression analyses were performed to find differentially abundant gut microbiome features and their associations with CSF biomarkers of AD and related pathologies.RESULTS Gut microbiome composition and function differed between people with AD and cognitively unimpaired individuals. The compositional difference was replicated in an independent cohort. Differentially abundant gut microbiome features were associated with CSF biomarkers of AD and related pathologies.DISCUSSION These findings enhance our understanding of alterations in gut microbial composition and function in AD, and suggest that gut microbes and their pathways are linked to AD pathology.Competing Interest StatementDr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix. Dr. Rob Knight is a scientific advisory board member, and consultant for BiomeSense, Inc., has equity and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. He is a cofounder of Micronoma, and has equity and is a scientific advisory board member. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Dr. Zetterberg has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Daniel McDonald is a consultant for, and has equity in, BiomeSence, Inc. The terms of this arrangement has been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest polices. Funding StatementThis project was enabled in part by The Alzheimer Gut Microbiome Project (AGMP) and the Alzheimer's Disease Metabolomics Consortium (ADMC) funded wholly or in part by the following NIA grants thereto: U01AG061359 and U19AG063744 awarded to Dr. Kaddurah-Daouk at Duke University in partnership with multiple academic institutions. As such, the investigators within the AGMP and the ADMC, not listed specifically in this publication's author's list, provided data along with its pre-processing and prepared it for analysis, but did not participate in analysis or writing of this manuscript. A listing of AGMP Investigators can be found at alzheimergut.org/meet-the-team/. A complete listing of ADMC investigators can be found at: sites.duke.edu/adnimetab/team/. The IGM S10 grant S10 OD026929 was awarded to Dr. Rob Knight at the University of California San Diego IGM Genomics Center. This publication includes data generated at the University of California San Diego IGM Genomics Center utilizing an Illumina NovaSeq 6000 that was purchased with funding from a National Institutes of Health SIG grant (#S10 OD026929). This work was also supported by the National Institute on Aging Grant R01AG070973 (B.B.B., F.E.R., T.K.U.), National Institute on Aging Grant R01AG083883 (T.K.U., B.B.B., F.E.R.), Vilas Early-Career Investigator Award (T.K.U.), and National Institute on Aging Grant P30AG062715 (which in part supported B.B.B., T.K.U.). Dr. Zetterberg is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (#2023-00356; #2022-01018 and #2019-02397), the European Union's Horizon Europe research and innovation programme under grant agreement No 101053962, Swedish State Support for Clinical Research (#ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (#201809-2016862), the AD Strategic Fund and the Alzheimer's Association (#ADSF-21-831376-C, #ADSF-21-831381-C, #ADSF-21-831377-C, and #ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Union's Horizon Europe Research and Innovation Programme and by the Participating States (NEuroBioStand, #22HLT07), the Bluefield Project, Cure Alzheimer's Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Ronstroms Stiftelse, Stiftelsen for Gamla Tjanarinnor, Hjarnfonden, Sweden (#FO2022-0270), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 860197 (MIRIADE), the European Union Joint Programme-Neurodegenerative Disease Research (JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, and the UK Dementia Research Institute at UCL (UKDRI-1003). COBAS is a trademark of Roche. All other product names and trademarks are the property of their respective owners. The NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Review Board (IRB) at the University of Wisconsin-Madison gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes